PFE ticks up after 340B court block as drug-pricing scrutiny returns
New York, Jan 8, 2026, 10:13 EST — Regular session
Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters
Why it matters now is less about a single day’s trade and more about the plumbing of drug pricing. The 340B program requires manufacturers to sell at steep discounts to eligible hospitals; small shifts in timing or mechanics can move net prices,…
